Compare Hubbell (HUBB) vs Kymera Therapeutics Inc. Common Stock (KYMR) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Hubbell vs Kymera Therapeutics Inc. Common Stock — how do they compare? Hubbell trades at $469.9 (market cap $25.25B), while Kymera Therapeutics Inc. Common Stock trades at $105.11 (market cap $8.87B). The key difference: Hubbell is far larger — about 2.8× Kymera Therapeutics Inc. Common Stock's market cap, and Hubbell pays a 1.19% dividend while Kymera Therapeutics Inc. Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Hubbell for 6 Days and Kymera Therapeutics Inc. Common Stock for 0 Days on average.
| HUBB | KYMR | |
|---|---|---|
Market Cap | $25.25B | $8.87B |
Volume | 443,319 | 779,107 |
Sector | Industrials | Health |
52-Week High | $557.85 | $127.31 |
52-Week Low | $407.36 | $55.80 |
Typical Hold Time | 6 Days | 0 Days |
Enterprise Value | $30.41B | $8.26B |
Dividend Yield | 1.19% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Hubbell Incorporated (HUBB) trades at $477.93, up 0.82% with a neutral technical signal. The stock shows strong fundamentals with consistent earnings beats (Q4 2025: $4.73 vs. $4.71 expected, Q1 2026: $3.93 vs. $3.87, Q2 2026: $5.52 vs. $5.39) and robust profitability (net margin 14.49%, ROE 24.34%). Recent news highlights grid modernization opportunities and institutional buying interest from Bank of America and BNY Mellon.
Hubbell presents a favorable outlook with analyst consensus price target of $560.50 (17% upside) and strong institutional support. Key risks include integration challenges from recent acquisitions and dependence on utility spending cycles. The Q3 2026 earnings report on October 27 will be crucial for validating growth trajectory amid electrification demand.
No Aura AI signal available yet.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Hubbell
Hubbell manufactures electrical and utility products used in transmission, distribution, and electrical infrastructure. Its portfolio includes components and systems for utilities, data centers, industrial facilities, and buildings.
Read more on HUBB →About Kymera Therapeutics Inc. Common Stock
Kymera Therapeutics, Inc. is a biopharmaceutical company developing small-molecule medicines based on targeted protein degradation, using its Pegasus platform to direct the body's natural protein-disposal system against disease-causing proteins.
Read more on KYMR →
